Related references
Note: Only part of the references are listed.OPTIMIZING IGG THERAPY IN CHRONIC AUTOIMMUNE NEUROPATHIES: A HYPOTHESIS DRIVEN APPROACH
Melvin Berger et al.
MUSCLE & NERVE (2015)
Biologics: An Update and Challenge of Their Pharmacokinetics
Shaojun Shi
CURRENT DRUG METABOLISM (2014)
Pharmacokinetics of intravenous immunoglobulin in multifocal motor neuropathy
Lotte Vlam et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2014)
Dosing Considerations for Obese Patients Receiving Cancer Chemotherapeutic Agents
Ronald G. Hall et al.
ANNALS OF PHARMACOTHERAPY (2013)
Subcutaneous immunoglobulin (16 or 20%) therapy in obese patients with primary immunodeficiency: a retrospective analysis of administration by infusion pump or subcutaneous rapid push
R. Shapiro
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2013)
Efficiency of immunoglobulin G replacement therapy in common variable immunodeficiency: correlations with clinical phenotype and polymorphism of the neonatal Fc receptor
V. Gouilleux-Gruart et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2013)
The Molecular and Biophysical Characterization of the Human Blood-Nerve Barrier: Current Concepts
Eroboghene E. Ubogu
JOURNAL OF VASCULAR RESEARCH (2013)
Chronic adipose tissue inflammation: all immune cells on the stage
Goekhan Cildir et al.
TRENDS IN MOLECULAR MEDICINE (2013)
Adverse Effects of IgG Therapy
Melvin Berger
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2013)
Pharmacokinetic Models for FcRn-Mediated IgG Disposition
Jim J. Xiao
JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY (2012)
Drug Dosing Based on Weight and Body Surface Area: Mathematical Assumptions and Limitations in Obese Adults
Manjunath P. Pai
PHARMACOTHERAPY (2012)
Bringing immunoglobulin knowledge up to date: how should we treat today?
S. Misbah et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2011)
Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies
Melvin Berger et al.
CLINICAL IMMUNOLOGY (2011)
Pharmacokinetic considerations in the obese
Yigal Leykin et al.
BEST PRACTICE & RESEARCH-CLINICAL ANAESTHESIOLOGY (2011)
Association of FcRn expression with lung abnormalities and IVIG catabolism in patients with common variable immunodeficiency
T. Freiberger et al.
CLINICAL IMMUNOLOGY (2010)
Impact of trough IgG on pneumonia incidence in primary immunodeficiency: A meta-analysis of clinical studies
Jordan S. Orange et al.
CLINICAL IMMUNOLOGY (2010)
Infection outcomes in patients with common variable immunodeficiency disorders: Relationship to immunoglobulin therapy over 22 years
Mary Lucas et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2010)
Monoclonal Antibody Pharmacokinetics and Pharmacodynamics
W. Wang et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Pharmacokinetics of Immunoglobulin Administered via Intravenous or Subcutaneous Routes
Francisco A. Bonilla
IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA (2008)
Biologic IgG level in primary immunodeficiency disease: The IgG level that protects against recurrent infection
Vincent R. Bonagura et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2008)
Safety of intravenous immunoglobulin (IVIG) therapy
Uriel Katz et al.
AUTOIMMUNITY REVIEWS (2007)
Adverse events associated with intravenous immunoglobulin therapy
DJ Hamrock
INTERNATIONAL IMMUNOPHARMACOLOGY (2006)
Pharmacokinetics of intravenous immunoglobulin: A systematic review
Tamar Koleba et al.
PHARMACOTHERAPY (2006)
Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases
N Li et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
Share Paper
